Health Care • Medical/Dental Instruments
$2.04 ▼ -0.11
(-5.12%)
MKT CAP: $4.0M • VOL: 54.6K
52W L $2 52W H $33
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
AMIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.0M | -$11.6M | -$12.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$16.7M | -$11.4M | -$15.4M |
| EBITDA (Normalized) | -$17.0M | -$11.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.3M | -$8.3M | -$6.6M |
| Capital Expenditures (CapEx) | $10.0K | $14.0K | — |
| Free Cash Flow (FCF) | -$12.3M | -$8.3M | -$6.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $9.9M | $11.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.6M | $9.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMIX.